Literature DB >> 26105425

PP103. Arterial stiffness in women with previous GDM - A follow up of Chinese HAPO study cohort.

W H Tam1, R C-W Ma2, J C-N Chan2, T T-H Lao1, M H-M Chan3, C-Y Li1.   

Abstract

INTRODUCTION: It is well known that women with history of gestational diabetes (GDM) are at risk of future DM. Whether they are at a higher risk of hypertension and cardiovascular risk remained to be determined.
OBJECTIVES: To determine whether Chinese women who have been diagnosed GDM according to the new IADPSG criteria have a higher risk of hypertension & arterial stiffness than women with normal glucose tolerance (NGT) during pregnancy.
METHODS: Chinese women who had participated in the HAPO study between 2001 and 2006 in Hong Kong were followed up at a median of 6years postpartum. All underwent anthropometric & BP measurements. Central systolic and diastolic blood pressures (SBP & DBP), augmentation index (AI) and pulse wave velocity (PWV) were assessed by using SphygmoCor(®) PVx.A total of 608 women (494 NGT, 114 GDM) were followed up till early 2012.
RESULTS: Although there was no significant difference in the rate of hypertension, the central SBP (106±12 vs 102±13mmHg, p=0.03), AI (22.1±8.3 vs 18.9±8.5%, p<0.001) and PWV (6.8±1.0 vs 6.6±0.8, p=0.03) were all higher in women with history of GDM.
CONCLUSION: The findings suggest a higher risk of subclinical atherosclerosis amongst women with GDM despite the blood pressure may appear normal at the time of follow up.
Copyright © 2012. Published by Elsevier B.V.

Entities:  

Year:  2012        PMID: 26105425     DOI: 10.1016/j.preghy.2012.04.214

Source DB:  PubMed          Journal:  Pregnancy Hypertens        ISSN: 2210-7789            Impact factor:   2.899


  1 in total

1.  Subclinical inflammation associated with prolonged TIMP-1 upregulation and arterial stiffness after gestational diabetes mellitus: a hospital-based cohort study.

Authors:  Tiina Vilmi-Kerälä; Anneli Lauhio; Taina Tervahartiala; Outi Palomäki; Jukka Uotila; Timo Sorsa; Ari Palomäki
Journal:  Cardiovasc Diabetol       Date:  2017-04-13       Impact factor: 9.951

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.